Prolia™, Xgeva® (denosumab) – New warning
January 31, 2017 – The FDA approved a new update to the Warnings and Precautions section of the Prolia (denosumab) and Xgeva (denosumab) drug labels regarding the risk of multiple vertebral fractures following discontinuation of denosumab treatment.
Download PDF
